PURE Bioscience, Inc.
PURE
$0.0688
$0.013825.09%
| Weiss Ratings | PURE - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
| Rating | ||||
| Reward Index | Very Weak | |||
| Risk Index | Weak | |||
| Risk Grade | D | |||
| Reward Grade | E | |||
| Rating Factors | PURE - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
| Dividend Index | -- | |||
| Growth Index | Fair | |||
| Efficiency Index | Very Weak | |||
| Solvency Index | Weak | |||
| Total Return Index | Weak | |||
| Volatility Index | Weak | |||
| Beta / Standard Deviation | PURE - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
| Beta | -0.58 | |||
| Price History | PURE - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
| 7-Day Total Return | 44.84% | |||
| 30-Day Total Return | -10.53% | |||
| 60-Day Total Return | -1.71% | |||
| 90-Day Total Return | -26.81% | |||
| Year to Date Total Return | 5.85% | |||
| 1-Year Total Return | -23.56% | |||
| 2-Year Total Return | -51.69% | |||
| 3-Year Total Return | -61.93% | |||
| 5-Year Total Return | -89.42% | |||
| 52-Week High % Change | -66.46% | |||
| 52-Week Low % Change | 22.22% | |||
| Price | PURE - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
| 52-Week High Price | $0.16 | |||
| 52-Week Low Price | $0.05 | |||
| 52-Week Low Price (Date) | Mar 10, 2025 | |||
| 52-Week High Price (Date) | Nov 15, 2024 | |||
| Valuation | PURE - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
| Market Cap | 6.15M | |||
| Enterprise Value | 9.32M | |||
| Price/Earnings (TTM) | -- | |||
| Earnings Per Share (TTM) | -0.03 | |||
| Earnings Per Share Growth | -10.81% | |||
| Price/Earnings To Growth | -- | |||
| Price/Sales (TTM) | 3.44 | |||
| Price/Book (Q) | -1.76 | |||
| Enterprise Value/Revenue (TTM) | 5.18 | |||
| Price | $0.07 | |||
| Enterprise Value/EBITDA (TTM) | -3.21 | |||
| Enterprise Value/EBIT | -3.06 | |||
| Market Cap Category | Nano Cap | |||
| Dividends and Shares | PURE - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
| Shares Outstanding | 111.86M | |||
| Dividend Yield | -- | |||
| Div. Per Share (Most Recent) | -- | |||
| Dividend Per Share (TTM) | -- | |||
| Payout Ratio (TTM) | -- | |||
| Dividend Per Share (Most Recent) | -- | |||
| Company Info | PURE - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
| Phone Number | 619 596 8600 | |||
| Address | 771 Jamacha Rd., #512 El Cajon, CA 92019 | |||
| Website | www.purebio.com | |||
| Country | United States | |||
| Year Founded | 1992 | |||
| Profitability | PURE - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
| Operating Margin (TTM) | -169.56% | |||
| Profit Margin | -183.86% | |||
| Management Effectiveness | PURE - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
| Return on Assets | -120.00% | |||
| Return on Equity | -- | |||
| Income Statement | PURE - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
| Revenue (TTM) | 1.80M | |||
| Total Revenue (TTM) | 1.80M | |||
| Revenue Per Share | $0.02 | |||
| Gross Profit (TTM) | 1.04M | |||
| EBITDA (TTM) | -2.90M | |||
| EBIT (TTM) | -3.05M | |||
| Net Income (TTM) | -3.30M | |||
| Net Income Avl. to Common (TTM) | -3.30M | |||
| Total Revenue Growth (Q YOY) | -22.99% | |||
| Earnings Growth (Q YOY) | 6.26% | |||
| EPS Diluted (TTM) | -0.03 | |||
| EPS Diluted Growth (Q YOY) | 6.06% | |||
| Balance Sheet | PURE - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
| Cash and Short-Term Inv. (Q) | 346.00K | |||
| Cash Per Share (Q) | $0.00 | |||
| Total Current Assets (Q) | 911.00K | |||
| Total Preferred Equity (Q) | -- | |||
| Total Equity (Q) | -3.50M | |||
| Current Ratio (Q) | 1.000 | |||
| Book Value Per Share (Q) | -$0.03 | |||
| Total Assets (Q) | 924.00K | |||
| Total Current Liabilities (Q) | 911.00K | |||
| Total Debt (Q) | 3.51M | |||
| Total Liabilities (Q) | 4.42M | |||
| Total Common Equity (Q) | -3.50M | |||
| Cash Flow | PURE - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
| Cash from Investing (TTM) | -- | |||
| Cash from Financing (TTM) | 1.50M | |||
| Net Change in Cash (TTM) | -1.09M | |||
| Levered Free Cash Flow (TTM) | -1.56M | |||
| Cash from Operations (TTM) | -2.59M | |||
